Gilead Connecticut, Inc.

James P Harding

Kevin S Currie

Scott A Mitchell

Peter A Blomgren

Jeffrey E Kropf

Jianjun Xu

Seung H Lee

David M Armistead

Zhongdong Zhao

Douglas Gregory Stafford

Antonio J M Barbosa, Jr

Soumya Mitra

Douglas G Stafford

Jr Antonio J Barbosa

Provided are imidazopyrazine compounds, particularly including 6-(benzo[d]thiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine, structure below, and methods and formulations for their use in inhibiting Spleen Tyrosine Kinase in treating conditions including B-cell lymphomas or leukemias and inflammatory conditions: 

6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine

Certain imidazopyrazines having the structure of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare as defined herein, and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Imidazopyrizine syk inhibitors

Certain imidazopyrazines of Formula (I) and pharmaceutical compositions thereof are provided herein.  Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Imidazopyrazine Syk inhibitors

Growing community of inventors

Loudonville, NY, United States of America

James P Harding